

Please replace the paragraph beginning at page 44, line 28 with the following

paragraph:

A8
--The results of these behavioral tests are shown in Figures 2A-2D and 3. Again, all three treated groups: NSC, bFGF, and the combination of NSC + bFGF, showed superiority in recovery on the forelimb and hindlimb placing tests compared to placebo. Again, there was a trend towards best recovery in the combination group. In the body swing test, NSC treatment alone did not show advantage over placebo, but both the bFGF and combination groups did. In the spontaneous limb use test, only the combination group showed a trend toward improved outcome. Finally, in the paw reaching test, the combination group appeared to show superiority compared to either treatment alone. Histological evaluation of these brains is still pending.--

In the claims:

✓ ✓
Please cancel claims 3 and 36-48.

Please amend claims 1, 13, 14, 15, 17, 27, 28, and 29 as follows:

- A9
1. (AMENDED) A method of treating a subject with CNS damage, said method comprising administering to said subject:
 - stem cells; and
 - a neural stimulantwherein the conjoint administration of cells and neural stimulant ameliorates the effects of CNS damage.

- Q10
13. (AMENDED) A method of claim 9 wherein said polypeptide growth factor is a polypeptide at least 30% identical to a bFGF polypeptide shown in one of SEQ ID Nos 1-3.
14. (AMENDED) A method of claim 12 wherein said polypeptide is identical to a bFGF polypeptide shown in one of SEQ ID Nos 1-3.
15. (AMENDED) A method of claim 1 wherein said neural stimulant is selected from the group consisting of: a neurotransmitter, a neurotransmitter agonist, a neurotransmitter antagonist, a differentiation factor, a guidance molecule and transcranial magnetic stimulation.

- Q11
17. (AMENDED) A method of treating a subject with brain damage resulting from stroke, said method comprising administering to said subject:
- stem cells; and
 - a neural stimulant
- wherein the conjoint treatment with cells and neural stimulant ameliorates the effects of brain damage.

- Q12
27. (AMENDED) A method of claim 23 wherein said polypeptide growth factor is a polypeptide at least 30% identical to a bFGF polypeptide shown in one of SEQ ID Nos 1-3.
28. (AMENDED) A method of claim 23 wherein said polypeptide is identical to a bFGF polypeptide shown in one of SEQ ID Nos 1-3.
29. (AMENDED) A method of claim 17 wherein said neural stimulant is selected from the group consisting of: a neurotransmitter agonist, a neurotransmitter antagonist, a differentiation factor, a guidance molecule and transcranial magnetic stimulation.